An Open, Phase I Study of Cediranib in Patients with Acute Myeloid Leukemia (AML).
Walter Fiedler(Universität Hamburg), Hubert Serve(Goethe University Frankfurt), Wolfgang E. Berdel(University Hospital Münster), Ute Zirrgiebel(Johannes Gutenberg University Mainz), Michael Heuser(Martin Luther University Halle-Wittenberg), Thomas A. Puchalski(Dana-Farber Cancer Institute), O. Ottman(Goethe University Frankfurt), Juliane M. Jürgensmeier(AstraZeneca (United Kingdom)), Rolf M. Mesters(University Hospital Münster), Sandra R. Brave(Tokyo Medical and Dental University), Jane Robertson(Cancer Research UK), Gerhard Ehninger(University Hospital Carl Gustav Carus)
Cited by 1
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k